Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 12;7(8):e1294.
doi: 10.1097/CCE.0000000000001294. eCollection 2025 Aug 1.

Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis

Tiffanie K Jones  1 , John P Reilly  1 , Brian J Anderson  1 , Todd A Miano  2 , Brijesh Karanam  1 , Caroline A G Ittner  1 , Michael G S Shashaty  1 , Rui Feng  2 , Nuala J Meyer  1
Affiliations
Free article

Soluble Fms-Like Tyrosine Kinase-1 Associates With Risk of Acute Respiratory Distress Syndrome and Mortality in Sepsis

Tiffanie K Jones et al. Crit Care Explor. .
Free article

Abstract

Importance: The vascular endothelial growth factor (VEGF) signaling pathway is important in the pathogenesis of acute respiratory distress syndrome (ARDS) with supportive genetic and proteomic evidence. Genetic polymorphisms within FLT1, which encodes VEGF receptor 1, associate with risk of ARDS in sepsis. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is a secreted splice variant of FLT1 that acts as a potent antagonist to circulating VEGF.

Objectives: To assess the association between early plasma concentrations of sFlt-1 and risk of ARDS and to determine if ARDS mediates the relationship between sFlt-1 and mortality during sepsis.

Design, setting, and participants: In a prospective cohort study, we enrolled 198 critically ill patients with sepsis per Sepsis-2 criteria. ARDS was defined per Berlin criteria.

Main outcomes and measures: Levels of sFlt-1 were quantified using electrochemiluminescence on plasma collected in the emergency department upon admission. We tested the association between plasma levels of sFlt-1 with ARDS and mortality using logistic regression adjusting for age, sex, and pulmonary versus nonpulmonary source of sepsis. We applied causal mediation analysis to determine the percentage of the total effect of sFlt-1 on mortality that was mediated by ARDS.

Results: We enrolled 198 patients; ARDS developed within 6 days in 29%. Plasma levels of sFlt-1 were significantly associated with risk of ARDS in sepsis (odds ratio [OR], 1.91 per log increase; 95% CI, 1.31-2.76 per log increase; p < 0.01). Plasma sFlt-1 levels were also associated with mortality (OR, 2.19 per log increase; 95% CI, 1.57-3.08 per log increase; p < 0.01). ARDS mediated 20.3% (95% CI, 6.9-98.1%) of the total effect of sFlt-1 on mortality (p < 0.01).

Conclusions and relevance: Higher plasma levels of sFlt-1 were associated with an increased risk of ARDS and ARDS mediated a significant proportion of the sFlt-1-associated mortality observed during sepsis. Our findings further implicate dysregulated VEGF signaling in ARDS and suggest that plasma sFlt-1 merits further investigation as an early endothelial therapeutic target for sepsis-associated ARDS and mortality.

Keywords: acute respiratory distress syndrome; mortality; sepsis.

PubMed Disclaimer

Conflict of interest statement

Dr. Meyer also reports consulting for GlaxoSmithKline, Novartis, and funding to her institution for Quantum Leap Healthcare Consortium outside of this work. The remaining authors have disclosed that they do not have any potential conflicts of interest.

References

    1. Bellani G, Laffey JG, Pham T, et al.; LUNG SAFE Investigators and the ESICM Trials Group: The LUNG SAFE study: A presentation of the prevalence of ARDS according to the Berlin definition! Crit Care 2016; 20:268
    1. Bellani G, Laffey JG, Pham T, et al.; LUNG SAFE Investigators: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315:788–800
    1. Auriemma CL, Zhuo H, Delucchi K, et al.: Acute respiratory distress syndrome-attributable mortality in critically ill patients with sepsis. Intensive Care Med 2020; 46:1222–1231
    1. Beitler JR, Schoenfeld DA, Thompson BT: Preventing ARDS: Progress, promise, and pitfalls. Chest 2014; 146:1102–1113
    1. Ranieri VM, Rubenfeld GD, Thompson BT, et al.; ARDS Definition Task Force: Acute respiratory distress syndrome: The Berlin definition. JAMA 2012; 307:2526–2533

Substances